Samatasvir

Samatasvir
Systematic (IUPAC) name
N-((1R)-2-((2S)-2-(5-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-3H-benzimidazol-5-yl)thieno(3,2-b)thiophen-3-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate
Clinical data
Legal status
  • Investigational
Routes of
administration		 Oral
Identifiers
CAS Number 1312547-19-5
PubChem CID 53302707
Chemical data
Formula C47H48N8O6S2
Molar mass 885.062 g/mol

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.[1]

Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5a replication complex.[2] While it showed promising results when administered as a monotherapy, it is most likely that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy, as with most other novel treatments for Hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir and ritonavir are also underway.[3]

References

  1. ↑ Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. PMID 24434503
  2. ↑ Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrobobial Agents and Chemotherapy. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. PMID 24867983
  3. ↑ Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
This article is issued from Wikipedia - version of the Friday, November 20, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.